Clinical Trials Browser

Phase 1 × Dasatinib × Thoracic × Clear all

Mesothelioma, Malignant

NCT01999985 2020-11-27

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Pleural Diseases, Pleural Effusion, Pleural Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Pleural Effusion, Malignant

NCT00444015 2017-02-23

Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

34 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00779389 2016-01-13

Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family

Phase 1 Completed

58 enrolled

Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms

Clinical Trials

Dasatinib in Resectable Malignant Pleural Mesothelioma

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)

Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family